Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Norvir Cost Chart Misrepresents Therapeutic Dose, Price – FDA Warning Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The pricing chart, created to explain a 2003 price increase, compares the cost of Norvir 100 mg daily to higher, labeled doses of other protease inhibitors, and implies that Norvir may be used as a monotherapy at a low dose, FDA said. The agency previously sent Abbott a letter citing Norvir promotional materials in 2001.

You may also be interested in...



Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says

A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.

Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says

A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.

Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price

Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.

Topics

UsernamePublicRestriction

Register

PS059654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel